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Clinical  Inquiries
Are inhalers with spacers
better than nebulizers 
for children with asthma?
■ EVIDENCE-BASED ANSWER
Metered-dose inhalers with a spacer (MDI/S) are
as good as, or better than, nebulizers for children
with asthma. This is based on numerous random-
ized controlled trials that compared outcomes
such as hospital admission rates, asthma severity
scores, and pulmonary function scores (strength
of recommendation: A, based on consistent 
randomized controlled trials and meta-analysis). 
■ EVIDENCE SUMMARY
A Cochrane review of 10 randomized controlled
trials comparing nebulizers with MDI/S, both in
adults and in children aged >2 years, showed a
substantial trend towards improvement in hos-
pital admission rates with MDI/S use. Sample
size for each study was small, ranging from 18
to 152 patients, with a total sample size of 880
children and 444 adults. 
The relative risk of admission for MDI/S vs
nebulizer for children was 0.65 (95% confidence
interval, 0.4–1.06). Secondary outcomes were
equivalent or slightly improved, including dura-
tion in the emergency department, changes in 
respiratory rate, blood gases, pulse, tremor, 
symptoms score, lung function, and use of
steroids. Patients with life-threatening asthma
(for example, those considered for ventilation)
or other chronic illnesses were excluded.1
All but 1 of these studies were set in the
emergency department and all involved the use
of one of a variety of spacers with the MDI, such
as the Aerochamber or Inspirease. Whether
these efficacy studies can be translated into
daily outpatient clinical practice remains
unclear. Emergency departments typically 
have higher staffing levels, and study subjects 
and their parents may have received more
MDI/S training than is practical in many office 
settings.
While most of the data were for children aged 
2 years and older, 1 study published after the
Cochrane review did show a lower admission
rate in 85 patients who were 2 to 24 months in
the MDI/S group.2 Controlling for the initial
Pulmonary Index score, children using an MDI
and Aerochamber spacer were admitted less
often (5% vs 20%, number needed to treat=7;
P=.05) than children using nebulizers. Since the
results of this single small trial are the only
data available for this younger age group, using
MDI/S instead of nebulizers should be done with
caution for children aged <2 years.
Another randomized controlled trial of 152
patients found no difference in primary outcomes
of asthma severity score, oxygen saturation,
and percent predicted peak expiratory flow rate
(PEFR). Several secondary outcomes slightly
favored MDI/S: number of treatments given,
whether steroids were used, change in heart
rate, side effects, rate of hospital admission,and
treatment time in the emergency department.3
A smaller double-blinded randomized con-
trolled trial of 33 children aged 6 to 14 years
showed no difference in MDI/S vs nebulizer, as
measured by clinical score, respiratory rate,
oxygen saturation, and forced expiratory volume
at 1 second (FEV1).
4 The researchers calculated
the study had 90% power to detect a clinically
meaningful difference in FEV1 of 12% of the 
predicted value between the groups. 
Other review articles reach the same conclu-
sion. One article reviewed the literature from
1980 to 1996 and examined 17 prospective 
clinical trials. Outcomes measured included 
pulmonary function measures and clinical
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scores. The researchers recommended that
MDI/S be used due to clinical benefit, safety,
lower cost, personnel time, and speed and ease
of administration.5
A review article from the British literature
examined 3 randomized controlled trials involving
51 patients and found no superiority of nebulizer
vs MDI/S.6 A similar review article examined 14
randomized controlled trials for beta-agonist
delivery for patients aged 5 to 15 with stable asth-
ma. They found no obvious benefit of 1 type of
device over another, including nebulizer, MDI/S,
and dry powder inhalers.7 These last 2 articles
claimed to be systematic reviews, although they
do not clearly state their search methodology.
Researchers used a wide variety of spacers in
all aforementioned studies; accordingly, one can-
not be recommended as superior to others. 
The degree of teaching given to parents and 
children about MDI/S use was not described in
any of the trials.
■ RECOMMENDATIONS FROM OTHERS
Guidelines from the Global Health Initiative for
Asthma, a collaboration of the National Heart,
Lung and Blood Institute and the World Health
Organization, recommend MDI/S for children with
asthma due to increased efficacy and decreased
cost (revised in 2002). Specifically, they recom-
mend a spacer with a face mask for infants and
preschool children, a mouthpiece and spacer for
children aged 4 to 6 years, and a dry powder
inhaler or breath-activated device from age 6
onwards.8 Cincinnati Children’s Hospital’s 
Using a spacer with a metered-
dose inhaler ensures that patients
receive more medication. Be sure
they follow these steps:
MDI with spacer is beneficial when used properlyF I G U R E  
• Shake the MDI/S several times
• Exhale completely
• Gently but firmly place lips 
around mouthpiece
• Spray one puff of medicine into
the spacer, and inhale slowly and
completely
• Hold breath and count to 10
before exhaling
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evidence-based guidelines from 1998 also recom-
mend MDI/S for children aged >1 year with acute
asthma exacerbations.9 This guideline suggests
using 4 to 8 puffs from a 90 µg albuterol MDI at
1- to 2-minute intervals every 20 minutes for 1
hour, then every 1 to 4 hours subsequently.
Julian T. Hsu, MD, Sandi Parker, MLIS,
University of Colorado Health Sciences Center, Denver
■ CLINICAL COMMENTARY
Use MDIs with spacers 
in all but the youngest patients
Until recently, using a nebulizer for the wheez-
ing child or infant seemed intuitively to be the
most effective way to deliver bronchodilators.
However, with recent data showing that MDIs
with spacers are just as effective, I have been
using MDIs with spacers for all but my
youngest patients. Parents as well as physi-
cians may need to be convinced that using less
technology in this case is better for their child.
In some cases, parental acceptance of therapy
necessitates using a nebulizer. 
Grant Hoekzema, MD, Mercy Family Medicine
Residency, St. Louis, Mo
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Do antipyretics 
prolong febrile illness?
■ EVIDENCE-BASED ANSWER
Antipyretics appear to have minor and variable
effects on the course of febrile illness. Aspirin and
acetaminophen do not prolong the course of rhi-
novirus illness, although they may prolong the
period of viral shedding and worsen nasal conges-
tion (strength of recommendation [SOR]: A–,
based on small randomized controlled trials). 
Acetaminophen did not affect symptoms, over-
all condition, or time to complete healing in chil-
dren with varicella, although it increased the time
to total scabbing of lesions (SOR: A, based on a
small randomized controlled trial). Aspirin and
acetaminophen may prolong influenza A illness
(SOR: C, based on a poor-quality, retrospective
observational study). 
Acetaminophen may prolong the course of
Shigella sonnei infection (SOR: B–, based on a
small retrospective cohort study). It does not
affect malaria cure rate, and there are insufficient
data to assess clearance of Plasmodium falciparum
(SOR: C, based on small randomized controlled
trials with heterogeneous results).  
■ EVIDENCE SUMMARY
Acetaminophen has a different mechanism of
action from other antipyretics. It halts the 
production of prostaglandin in the brain but not in
C O N T I N U E D
